Undercarboxylated osteocalcin in patients with newly diagnosed type 2 diabetes after blood glucose regulation (original) (raw)

Polish Archives of Internal Medicine

RESEARCH LETTER Undercarboxylated osteocalcin and newly diagnosed type 2 diabetestion studies are required to clarify the effects of improved glycemic control on this marker. The present study aimed to investigate the association and changes of serum ucOC levels and glycated hemoglobin A 1c (HbA 1c) in patients with type 2 diabetes over 3 months of lifestyle improvement. Patients and methods This study included 57 consecutive male and female patients with type 2 diabetes (according to the World Health Organization criteria), aged between 19 and 79 years. The exclusion criteria were as follows: malignant diseases, kidney or liver diseases, metabolic bone disorders, glucocorticoid treatment, hormonal contraception, hormone replacement therapy, and androgen treatment. Participants were outpatients or inpatients at the Department of Internal Medicine, Zagreb Clinical Hospital Centre. All patients were examined by the same specialist throughout the study. Clinical assessment included the measurement of height, weight, body mass index (BMI), as well as calculation of the homeostatic model assessment of insulin resistance (HOMA-IR) and insulin sensitivity (HOMA_%S). The values were calculated from fasting BG (FBG) and fasting insulin using the HOMA calculator (https://www. dtu.ox.ac.uk/homacalculator/). Blood was collected at baseline and at 3-month follow-up after overnight fasting. Six biochemical parameters were measured: ucOC (Takara Bio Inc., Kusatsu, Shiga, Japan), TOC, FBG, fasting insulin, HbA 1c , and bone turnover marker (crosslaps telopeptide), measured using Roche instruments and reagents (